Mainz Biomed Reports Positive Topline Results From Pooled Study Evaluating Novel MRNA Biomarkers and Proprietary AI Algorithm for Integration Into Pivotal FDA PMA Clinical Trial for Next Generation Colorectal Cancer Diagnostic

Groundbreaking topline results demonstrated sensitivity for colorectal cancer of 92% with specificity of 90% and best-in-class sensitivity for advanced adenoma of 82%690 subjects analyzed including previously unexamined

GlobeNewswireApr 25 21:29

Mainz Biomed Announces Upcoming Annual Meeting

TipRanksApr 24 18:59

Mainz Biomed Secures New Funding Agreement

TipRanksApr 19 19:29

Cantor Fitzgerald Inc.: Mainz Biomed (MYNZ.US) neutral rating confirmed.

Cantor Fitzgerald Inc.: Mainz Biomed (MYNZ.US) neutral rating confirmed.

Zhitong FinanceApr 12 22:01

Cantor Fitzgerald Reiterates Neutral on Mainz Biomed

Cantor Fitzgerald analyst Ross Osborn reiterates Mainz Biomed (NASDAQ:MYNZ) with a Neutral.

BenzingaApr 12 21:58

Analysts' Top Healthcare Picks: Mainz Biomed B.V. (MYNZ), Century Therapeutics (IPSC)

TipRanksApr 12 18:20